What Makes Praxis Precision Medicines, Inc. (PRAX) a Strong Momentum Stock: Buy Now?Zacks Investment Research • 03/08/24
Wall Street Analysts Think Praxis Precision Medicines, Inc. (PRAX) Could Surge 134.35%: Read This Before Placing a BetZacks Investment Research • 03/06/24
Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/05/24
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsGlobeNewsWire • 03/05/24
Praxis Precision Medicines to Participate in TD Cowen's 44th Annual Health Care ConferenceGlobeNewsWire • 03/01/24
Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public OfferingGlobeNewsWire • 01/11/24
Praxis Precision Medicines, Inc. (PRAX) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research • 01/09/24
Praxis Precision Medicines, Inc. (PRAX) Just Flashed Golden Cross Signal: Do You Buy?Zacks Investment Research • 01/05/24
Wall Street Analysts Believe Praxis Precision Medicines, Inc. (PRAX) Could Rally 494.95%: Here's is How to TradeZacks Investment Research • 11/30/23
Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming MeetingsGlobeNewsWire • 11/28/23
Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare ConferenceGlobeNewsWire • 11/21/23
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental EpilepsiesGlobeNewsWire • 11/16/23
Praxis Precision Medicines, Inc. (PRAX) Loses -32.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 11/14/23
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsGlobeNewsWire • 11/07/23
Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International CongressGlobeNewsWire • 08/28/23
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsGlobeNewsWire • 08/09/23
Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for UlixacaltamideGlobeNewsWire • 08/08/23
Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 StudyGlobeNewsWire • 08/07/23
Praxis Precision Medicines to Participate at the 2023 Wedbush PacGrow Healthcare ConferenceGlobeNewsWire • 08/03/23